Pharmaceutical maker ScinoPharm Taiwan Ltd (台灣神隆) is expected to see its profit increase by 12.7 percent this year on the back of several new drug launches after reporting record earnings for last year, SinoPac Securities Investment Service Co (永豐投顧) forecast.
“We expect that the seven new drugs ScinoPharm Taiwan is about to launch this year will increase its profits since the company can always accurately forecast the timing of its new drug launches and it maintained good relationships with its major global clients, including Teva and Sandoz,” SinoPac Securities said in a report on Thursday.
ScinoPharm opened two local production lines at the end of last year, and the company’s sales of cancer drugs and central nervous system drugs, which account for 89 percent of its revenue, have grown steadily, the report said.
Based on SinoPac’s report, ScinoPharm plans to launch two drugs in Japan and five in the US this year.
SinoPac has predicted that the pharmaceutical maker would see its net profit increase 12.7 percent to NT$1.32 billion (US$44.29 million) this year, or earnings per share of NT$2.03. Revenue is also likely to climb 14.8 percent to NT$5.22 billion this year, it said.
However, SinoPac still retained the rating of ScinoPharm shares as “neutral” because of the high price-earnings ratio of its shares.
SinoPac suggested that investors interested in buying the stock wait until its share price goes down.
The forecasts came after ScinoPharm last week posted NT$1.17 billion in net profit last year, up 21.75 pecent from 2011. Earnings per share were NT$1.8 last year, compared with NT$1.51 the previous year.
Consolidated revenue increased 15.8 pecent to NT$4.57 billion last year from NT$3.95 billion a year ago because of rising production efficiency, higher yield rate of its products and the company’s move to outsource part of its drug production, ScinoPharm said on Wednesday.
The 15.8 percent revenue growth of the company last year was higher than the 1.6 percent growth in 2011 and 2.6 percent growth in 2010, according to the company.
ScinoPharm Taiwan said earlier this year that the Japanese government was encouraging hospitals there to use more generic drugs because they are cheaper, which is a business opportunity for ScinoPharm.
Furthermore, ScinoPharm Taiwan would also benefit from the Chinese government’s attempt to increase the Chinese medicine market by 20 percent a year and the higher standards China has imposed on drug manufacturing factories, SinoPac said.
China has claimed a breakthrough in developing homegrown chipmaking equipment, an important step in overcoming US sanctions designed to thwart Beijing’s semiconductor goals. State-linked organizations are advised to use a new laser-based immersion lithography machine with a resolution of 65 nanometers or better, the Chinese Ministry of Industry and Information Technology (MIIT) said in an announcement this month. Although the note does not specify the supplier, the spec marks a significant step up from the previous most advanced indigenous equipment — developed by Shanghai Micro Electronics Equipment Group Co (SMEE, 上海微電子) — which stood at about 90 nanometers. MIIT’s claimed advances last
ISSUES: Gogoro has been struggling with ballooning losses and was recently embroiled in alleged subsidy fraud, using Chinese-made components instead of locally made parts Gogoro Inc (睿能創意), the nation’s biggest electric scooter maker, yesterday said that its chairman and CEO Horace Luke (陸學森) has resigned amid chronic losses and probes into the company’s alleged involvement in subsidy fraud. The board of directors nominated Reuntex Group (潤泰集團) general counsel Tamon Tseng (曾夢達) as the company’s new chairman, Gogoro said in a statement. Ruentex is Gogoro’s biggest stakeholder. Gogoro Taiwan general manager Henry Chiang (姜家煒) is to serve as acting CEO during the interim period, the statement said. Luke’s departure came as a bombshell yesterday. As a company founder, he has played a key role in pushing for the
EUROPE ON HOLD: Among a flurry of announcements, Intel said it would postpone new factories in Germany and Poland, but remains committed to its US expansion Intel Corp chief executive officer Pat Gelsinger has landed Amazon.com Inc’s Amazon Web Services (AWS) as a customer for the company’s manufacturing business, potentially bringing work to new plants under construction in the US and boosting his efforts to turn around the embattled chipmaker. Intel and AWS are to coinvest in a custom semiconductor for artificial intelligence computing — what is known as a fabric chip — in a “multiyear, multibillion-dollar framework,” Intel said in a statement on Monday. The work would rely on Intel’s 18A process, an advanced chipmaking technology. Intel shares rose more than 8 percent in late trading after the
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) has appointed Rose Castanares, executive vice president of TSMC Arizona, as president of the subsidiary, which is responsible for carrying out massive investments by the Taiwanese tech giant in the US state, the company said in a statement yesterday. Castanares will succeed Brian Harrison as president of the Arizona subsidiary on Oct. 1 after the incumbent president steps down from the position with a transfer to the Arizona CEO office to serve as an advisor to TSMC Arizona’s chairman, the statement said. According to TSMC, Harrison is scheduled to retire on Dec. 31. Castanares joined TSMC in